Metabolic research
An investigational multi-receptor agonist; approval status must be checked with local regulators.
An investigational multi-receptor agonist; approval status must be checked with local regulators.
Evidence map
Evidence levels describe study design. They do not by themselves establish safety or effectiveness.
Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.
The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.
Future GLP-1 receptor co-agonists and their cardiac effects.
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
A Study of LY3437943 in Participants With Type 2 Diabetes
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.
The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.
Counterfeit retatrutide product causes serious AEs
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide
Phase III retatrutide study demonstrates 30% weight loss
Retatrutide
Health news round-up: Alzheimer's treatment, retatrutide results and kidney cancer guidelines
Retatrutide
Retatrutide-Induced Intractable Diarrhea
Cryo-EM structure of GLP1 complex bound with Retatrutide
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Pharmacological management of obesity: Current landscape and emerging therapies.
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.
Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Pharmacological management of obesity: Current landscape and emerging therapies.
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Pre-approval Expanded Access of Retatrutide (LY3437943)
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Connected data hub
Reviewed records carry an admin-reviewed badge. Automated records link back to the provider for independent checking.
Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilogram per square...
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity...
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who...
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM) following 16 weeks of...
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which...
The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2...
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up...
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of...
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study...
The study is conducted in two parts (Part A and B). The main purpose of this study is to look at the amount of the LY3437943 that gets into the blood stream and how long it takes the...
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last...
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive...
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who...
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are...
The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the...
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable...
This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream...
Atal S, Agrawal C, Gupta R, Sadasivam B
Yovera-Aldana M, Manrique-Hurtado H, Umpierrez GE
Mehetre KN, Dawane JS
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y
Kim JY, Kim NH
Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, Pereira HMG
Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C
Kaczynski MM, Zureikat RM, Kaczynski MR, Sitarz R, Karakuła-Juchnowicz H
Mizdrak M, Batistić D, Mizdrak I
Neumann J, Kirchefer U, Hofmann B, Gergs U
Moiz A, O'Keefe EL, O'Keefe JH
Comisi JC
Ravic M, Srejovic IM, Milosavljevic I, Novakovic J, Jakovljevic V, Vucicevic K, Petrovic D, Muric M
Teofilović B, Trkulja J, Grujić-Letić N, Gligorić E, Baletic D, Tomić L, Mesarović A, Rašković A
Yovera-Aldana M, Manrique-Hurtado H, Umpierrez GE · JCEM case reports
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y · BMJ medicine
Kaczynski MM, Zureikat RM, Kaczynski MR, Sitarz R, Karakuła-Juchnowicz H · Biomedicines
Mizdrak M, Batistić D, Mizdrak I · Medical Sciences
Branine N · Cureus
Atal S, Agrawal C, Gupta R, Sadasivam B · Indian journal of pharmacology
Moiz A, O'Keefe EL, O'Keefe JH · Missouri medicine
Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, Pereira HMG · Rapid communications in mass spectrometry : RCM
· Springer Science and Business Media LLC
Opeyemi Komolafe · American College of Physicians
· Royal Pharmaceutical Society
· Royal Pharmaceutical Society
· Springer Science and Business Media LLC
L. Zhao, H.E. Xu, Q. Yuan · Worldwide Protein Data Bank
Nathan Ramsbacher · American Diabetes Association
· American Chemical Society (ACS)
Vasiliki K. Katsi, Georgios Koutsopoulos, Christos Fragoulis, Kyriakos S. Dimitriadis, Konstantinos P Tsioufis · Biomolecules · 22 citations
Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao et al. · Cell Discovery · 29 citations
Arun Jayant Sanyal, Lee M. Kaplan, Juan P. Frías, Bram Brouwers, Qiwei Wu, Melissa K. Thomas et al. · Nature Medicine · 293 citations
Manmeet Kaur, Saurav Misra · European Journal of Clinical Pharmacology · 51 citations
Muhammad Naeem, Laiba Imran, Umm E Salma Shabbar Banatwala · Health Science Reports · 30 citations
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz et al. · New England Journal of Medicine · 1110 citations
Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, Yu Du, Jitong Lou, Sirel Gurbuz et al. · The Lancet · 409 citations
Sheila Anne Doggrell · Expert Opinion on Investigational Drugs · 34 citations
Live discovery
Live results from PubMed, ClinicalTrials.gov and UniProt. These may not yet have been reviewed or stored in the Data Hub.
Fitzbio provides educational and research reference material. It does not diagnose, prescribe or replace advice from a qualified healthcare professional.
